opportunities. However, at the same time it has also brought in focus, high valuations of stocks like Keryx Biopharmaceuticals ( KERX ) that appreciated more than 100% in last one year and more than 400% since 2012. Investor interest in
we wrote about in a positive light last year because of an excellent chance of long-term success is Keryx Pharmaceuticals ( KERX ) . We accurately predicted the price run-up and wrote, We believe Keryx can run up to about $10 a share before the near
Shareholders of Keryx Biopharmaceuticals ( KERX ) want to give Congress a hug after its proposal to delay putting ESRD drugs into to the ACA-mandated payment bundle until 2024
Top 10 Gainers: ISR +26% . OTCQB:XXII +20% . ETAK +18% . KERX +18% . FFHL +17% . CXDC +14% . YONG +13% . EMAN +13% . SCS +12% . THTI +12% . Top 10 Losers: EXEL -36% . BODY
Keryx Biopharmaceuticals ( KERX ) Q4 2013 Earnings Conference ..... Greetings and welcome to the Keryx Biopharmaceuticals Investor Conference Call ..... Chief Financial Officer for Keryx Biopharmaceuticals . Thank you sir, you may
Keryx Biopharmaceuticals ( KERX ): Q4 EPS of -$0.21 misses by $0.05 . Press Release Post your comment!
(Reuters) - Keryx Biopharmaceuticals Inc's kidney drug proved effective in treating chronic kidney disease patients not on dialysis, sending the company's shares to a seven-year high on hopes the...
By Quoth the Raven : Introduction In an effort to find niche investing moves that I feel most traders don't take advantage of, I spent a day brainstorming with a friend of mine over some of the lesser used "tricks" we sometimes use to invest. These are small items that we've learned over time that
(Reuters) - Keryx Biopharmaceuticals Inc and Aeterna Zentaris said their experimental colorectal cancer drug did not meet the main goal of a late-stage trial, raising doubts on the drug's future as a...
We are no longer providing equity research on Keryx Biopharmaceuticals KERX . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.